[Current problems and new developments in therapy of mycoses (author's transl)].
Mycoses for most of them) represent a group of infectious diseases which seem to increase steadily although numerous fungicidal or fungistatic therapeutics are available. A severe problem is provided by the so-called opportunistic fungi which become parasitic only after the host's immunological protection has been impaired by predisposing factors. Therapy resistance and prevention of relapse are problems of a general nature in the therapy of mycoses. As special topics local treatment of dermatophytoses, of Candida mycoses, and new development in systemic treatment of deep mycoses are discussed.
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D003022:Clotrimazole / Q000627:therapeutic use; D003453:Cryptococcosis / Q000188:drug therapy; D003881:Dermatomycoses / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D005437:Flucytosine / Q000627:therapeutic use; D005658:Fungi / Q000187:drug effects*; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D008825:Miconazole / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents; D006118:Griseofulvin; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine; D003022:Clotrimazole
Aktuelle Probleme und neuere Entwicklungen in der Therapie der Mykosen